Clin Exp Vaccine Res.  2019 Jul;8(2):136-139. 10.7774/cevr.2019.8.2.136.

Plant factory: new resource for the productivity and diversity of human and veterinary vaccines

• Shim BS
• Hong KJ
• Maharjan P
• Choe S

• KMID: 2455086
• DOI: http://doi.org/10.7774/cevr.2019.8.2.136

Abstract

Vaccination is one of the most successful strategies to prevent diseases caused by pathogens. Although various expression systems including Escherichia coli, yeast, insect, and mammalian cells are currently used for producing many of vaccines, these conventional platforms have the limitation of post-translational modification, high cost, and expensive scalability. In this respect, the plant-based expression system has been considered as an attractive platform to produce recombinant vaccines due to fast, cost-effective and scalable production as well as safety. This review discusses the development of plant-derived vaccines and the current stage of plant-based expression system.

Keyword

Transgenic plants; Vaccines; Pharmaceuticals; Antibodies

MeSH Terms

Antibodies
Efficiency*
Escherichia coli
Humans*
Insects
Plants*
Plants, Genetically Modified
Protein Processing, Post-Translational
Vaccination
Vaccines*
Vaccines, Synthetic
Yeasts
Antibodies
Vaccines
Vaccines, Synthetic

Reference

1. Landry N, Pillet S, Favre D, et al. Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens. Clin Immunol. 2014; 154:164–177. PMID: 25128897.

2. Hiatt A, Cafferkey R, Bowdish K. Production of antibodies in transgenic plants. Nature. 1989; 342:76–78. PMID: 2509938.

3. Takeyama N, Kiyono H, Yuki Y. Plant-based vaccines for animals and humans: recent advances in technology and clinical trials. Ther Adv Vaccines. 2015; 3:139–154. PMID: 26668752.

4. Zhang H, Huang RY, Jalili PR, et al. Improved mass spectrometric characterization of protein glycosylation reveals unusual glycosylation of maize-derived bovine trypsin. Anal Chem. 2010; 82:10095–10101. PMID: 21077632.

5. Arntzen C. Plant-made pharmaceuticals: from ‘Edible Vaccines’ to Ebola therapeutics. Plant Biotechnol J. 2015; 13:1013–1016. PMID: 26345276.

6. Chichester JA, Jones RM, Green BJ, et al. Safety and immunogenicity of a plant-produced recombinant hemagglutinin-based influenza vaccine (HAI-05) derived from A/Indonesia/05/2005 (H5N1) influenza virus: a phase 1 randomized, double-blind, placebo-controlled, dose-escalation study in healthy adults. Viruses. 2012; 4:3227–3244. PMID: 23202523.

7. Landry N, Ward BJ, Trepanier S, et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One. 2010; 5:e15559. PMID: 21203523.

8. Cummings JF, Guerrero ML, Moon JE, et al. Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: a phase 1 dose-escalation study in healthy adults. Vaccine. 2014; 32:2251–2259. PMID: 24126211.

9. Tacket CO, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen CJ. Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes. J Infect Dis. 2000; 182:302–305. PMID: 10882612.

10. Kapusta J, Modelska A, Figlerowicz M, et al. A plant-derived edible vaccine against hepatitis B virus. FASEB J. 1999; 13:1796–1799. PMID: 10506582.

11. Thanavala Y, Mahoney M, Pal S, et al. Immunogenicity in humans of an edible vaccine for hepatitis B. Proc Natl Acad Sci U S A. 2005; 102:3378–3382. PMID: 15728371.

12. Yusibov V, Hooper DC, Spitsin SV, et al. Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. Vaccine. 2002; 20:3155–3164. PMID: 12163267.

13. Vermij P, Waltz E. USDA approves the first plant-based vaccine. Nat Biotechnol. 2006; 24:233–234.

14. Margolin E, Chapman R, Williamson AL, Rybicki EP, Meyers AE. Production of complex viral glycoproteins in plants as vaccine immunogens. Plant Biotechnol J. 2018; 6. 11. [Epub]. DOI: 10.1111/pbi.12963.

15. D'Aoust MA, Couture MM, Charland N, et al. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol J. 2010; 8:607–619. PMID: 20199612.

16. Shoji Y, Farrance CE, Bautista J, et al. A plant-based system for rapid production of influenza vaccine antigens. Influenza Other Respir Viruses. 2012; 6:204–210. PMID: 21974811.

17. Rosales-Mendoza S, Nieto-Gomez R, Angulo C. A perspective on the development of plant-made vaccines in the fight against Ebola virus. Front Immunol. 2017; 8:252. PMID: 28344580.

18. Streatfield SJ. Plant-based vaccines for animal health. Rev Sci Tech. 2005; 24:189–199. PMID: 16110888.

19. Bardor M, Faveeuw C, Fitchette AC, et al. Immunoreactivity in mammals of two typical plant glyco-epitopes, core alpha(1,3)-fucose and core xylose. Glycobiology. 2003; 13:427–434. PMID: 12626420.

20. Strasser R, Stadlmann J, Schahs M, et al. Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotechnol J. 2008; 6:392–402. PMID: 18346095.

21. Rosales-Mendoza S, Salazar-Gonzalez JA, Decker EL, Reski R. Implications of plant glycans in the development of innovative vaccines. Expert Rev Vaccines. 2016; 15:915–925. PMID: 26890067.